{
    "clinical_study": {
        "@rank": "105793", 
        "arm_group": [
            {
                "arm_group_label": "Sequence A", 
                "arm_group_type": "Active Comparator", 
                "description": "2 weeks, 6 week washout, 2 weeks"
            }, 
            {
                "arm_group_label": "Sequence B", 
                "arm_group_type": "Active Comparator", 
                "description": "2 weeks, 6 week washout, 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare local and systemic pharmacokinetics of tenofovir reduced-glycerin 1% gel after 2\n      weeks of daily rectal use and after 2 weeks of daily vaginal use"
        }, 
        "brief_title": "Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel", 
        "condition": "HIV Prevention", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 21 through 45 years (inclusive) at Screening\n\n          2. Able and willing to provide written informed consent\n\n          3. Able and willing to comply with all study procedure requirements, including, clinical\n             and laboratory assessments, vaginal and rectal examinations, urine and blood testing,\n             as well as attendance at all scheduled study visits\n\n          4. In general good health at Screening and Enrollment as determined by the Investigator\n             of Record (IoR)/ or designee\n\n          5. Negative pregnancy test at Screening and Enrollment\n\n          6. HIV-negative at Screening and Enrollment\n\n          7. Able and willing to provide adequate locator information\n\n          8. Willingness to use study-provided male condoms for the duration of study\n             participation for penetrative intercourse\n\n          9. Per participant report at Screening, regular menstrual cycles with at least 21 days\n             between menses (does not apply to participants who report using a progestin-only\n             method of contraception at screening, e.g., Depo-Provera, progesterone-containing\n             IUDs or extended use of oral contraceptives)\n\n         10. Per participant report at Enrollment, using an effective method of contraception and\n             intending to use an effective method for the duration of study participation;\n             effective methods include:\n\n               -  Hormonal methods, excluding vaginal rings\n\n               -  Intrauterine device (IUD) inserted at least 42 days prior to Enrollment (but not\n                  past the maximum length of recommended usage according to package instructions)\n\n               -  Sterilization of participant or partner at least 42 days prior to Enrollment\n\n               -  Self-identifies as a woman who has sex with women exclusively\n\n               -  Sexually abstinent for the at least 90 days prior to enrollment and the\n                  intention to remain sexually abstinent for the duration of study participation\n\n         11. Per participant report at Screening, states a willingness to refrain from inserting\n             any non-study vaginal or rectal products or objects into the vagina or rectum,\n             including but not limited to, spermicides, female condoms, diaphragms, contraceptive\n             vaginal rings, vaginal medications, menstrual cups, cervical caps (or any other\n             vaginal barrier method), vaginal/rectal douches, enemas, non-study approved\n             lubricants, sex toys (vibrators, dildos, etc.), and tampons for the duration of the\n             study product use periods and for 24 hours prior to each scheduled study clinic\n             visit.\n\n         12. Pap result consistent with Grade 0 according to the Female Genital Grading Table for\n             Use in Microbicide Studies Addendum 1 to the Division of AIDS (DAIDS) Table for\n             Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December\n             2004 (Clarification dated August 2009) or satisfactory evaluation of non-Grade 0 Pap\n             result with no treatment required per clinical judgment of IoR or designee in the 12\n             calendar months prior to the Enrollment Visit\n\n         13. At Screening, participant agrees not to take part in other research studies involving\n             drugs, medical devices, or vaginal/rectal products for the duration of study\n             participation (including the time between the Screening and Enrollment visits)\n\n             Participants in the biopsy subset must also meet the following criteria at Screening\n             to be eligible for inclusion:\n\n         14. Willing to abstain from inserting anything into the vagina or rectum for 72 hours\n             prior to and following the collection of these samples, including vaginal and rectal\n             intercourse\n\n         15. Willing to restrict the use of non-steroidal anti-inflammatory drugs (NSAIDs),\n             aspirin and/or other drugs that are associated with the increased likelihood of\n             bleeding following mucosal biopsy collection for 72 hours prior to and following the\n             collection biopsies\n\n        Exclusion Criteria:\n\n          1. Participant report of any of the following:\n\n               1. Known adverse reaction to the study product (ever)\n\n               2. Known adverse reaction to latex (ever)\n\n               3. Current male sex partner with known history of adverse reaction to latex (ever)\n\n               4. History of serum HBsAg positivity (ever)\n\n               5. Non-therapeutic injection drug use in the 12 calendar months prior to Enrollment\n\n               6. STI or reproductive tract infection (RTI) requiring treatment in the 6 calendar\n                  months prior to Enrollment\n\n               7. Post-exposure prophylaxis (PEP) for possible HIV-1 infection within the 6\n                  calendar months prior to Enrollment\n\n               8. Last pregnancy outcome within 90 days or less prior to Enrollment\n\n               9. Gynecologic or genital procedure (e.g., tubal ligation, dilation and curettage)\n                  within the 42 days prior to Enrollment Note: This does not include biopsy for\n                  the evaluation of an abnormal pap result or endometrial biopsy that occurred\n                  more than 7 days prior to Enrollment, provided that all other\n                  inclusion/exclusion criteria are met.\n\n              10. Participation in any other research study involving drugs, medical devices or\n                  vaginal products 42 days or less prior to Enrollment\n\n              11. Anticipated IUD replacement within the next 3 months or an IUD inserted 42 days\n                  or less prior to Enrollment\n\n              12. Participant report at Screening and/or Enrollment intention of becoming pregnant\n                  in the next 3 months\n\n              13. Currently breastfeeding at the time of Screening and/or Enrollment\n\n              14. History of bleeding problems (Participants in the biopsy subset only)\n\n          2. Laboratory abnormalities at Screening greater than or equal to a Grade 2*:\n\n               1. Aspartate aminotransferase (AST) or alanine transaminase (ALT)\n\n               2. Hemoglobin\n\n               3. Platelet count\n\n               4. Serum creatinine Otherwise eligible participants with an exclusionary test\n                  result(s) listed above may be re-tested during the screening process. If a\n                  participant is re-tested and a non-exclusionary result is documented within the\n                  42 days of providing informed consent, the participant may be enrolled.\n\n          3. Urinary tract infection (UTI) at Screening and/or Enrollment Note: Otherwise eligible\n             participants diagnosed with UTI during Screening will be offered treatment and may be\n             enrolled after completing treatment and all symptoms have resolved. If treatment is\n             completed and symptoms have resolved within 42 days of obtaining informed consent,\n             the participant may be enrolled.\n\n          4. Pelvic inflammatory disease or an STI or RTI requiring treatment per current WHO\n             guidelines at Screening and/or Enrollment\n\n          5. Clinically apparent Grade 2 or higher pelvic** and/or rectal*** examination finding\n             (observed by study staff) at Screening and/or Enrollment Note: Cervical bleeding\n             associated with speculum insertion and/or specimen collection judged to be within the\n             range of normal according to the clinical judgment of the IoR/designee is considered\n             expected non-menstrual bleeding and is not exclusionary.\n\n             Note: Otherwise eligible participants with exclusionary pelvic and/or rectal\n             examination findings may be enrolled/randomized after the findings have improved to a\n             non-exclusionary severity grading or resolved. If improvement to a non-exclusionary\n             grade or resolution is documented within 42 days of providing informed consent, the\n             participant may be enrolled.\n\n          6. Any other condition that, in the opinion of the IoR/designee, would preclude informed\n             consent, make study participation unsafe, complicate interpretation of study outcome\n             data, or otherwise interfere with achieving the study objectives\n\n               -  per the Division of AIDS Table for Grading the Severity of Adult and Pediatric\n                  Adverse Events Version 1.0, December, 2004 (Clarification dated August 2009) **\n                  per the Division of AIDS Table for Grading the Severity of Adult and Pediatric\n                  Adverse Events Version 1.0, December, 2004 (Clarification dated August 2009),\n                  Addendum 1 Female Genital Grading Table for Use in Microbicide Studies *** per\n                  the Division of AIDS Table for Grading the Severity of Adult and Pediatric\n                  Adverse Events Version 1.0, December, 2004 (Clarification dated August 2009),\n                  Addendum 3 Rectal Grading Table for Use in Microbicide Studies (Clarification\n                  dated May 2012)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768962", 
            "org_study_id": "MTN-014", 
            "secondary_id": [
                "5UM1AI068633-07", 
                "11885"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Sequence A", 
                "description": "Vaginal", 
                "intervention_name": "Once Daily Application of TFV RG 1% Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence A", 
                "intervention_name": "Once Daily Application of TFV RG 1% gel  - Rectal", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence B", 
                "intervention_name": "Once Daily Application of TFV RG 1% gel - Rectal", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence B", 
                "intervention_name": "Once Daily Application of TFV RG 1% Gel - Vaginal", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glycerol", 
                "Tenofovir", 
                "Tenofovir disoproxil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Microbicides", 
            "Tenofovir", 
            "Reduced-glycerin", 
            "Vaginal use", 
            "Rectal use", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "contact": {
                "email": "jj2158@columbia.edu", 
                "last_name": "Jessica Justman, MD", 
                "phone": "212-342-0537"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "Center for Infectious Disease Epidemiologic Research, Mailman School of Public Health, Columbia University"
            }, 
            "investigator": {
                "last_name": "Jessica Justman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Crossover Trial Evaluating the Pharmacokinetics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women", 
        "other_outcome": [
            {
                "description": "Correlate drug levels in rectal and genital fluids with drug potency", 
                "measure": "Inhibition of HIV by study drug in rectal and genital fluids", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }, 
            {
                "description": "Determine changes in microflora biomarkers and gene expression from the vaginal and rectal environments after 2 weeks of daily rectal versus 2 weeks of daily vaginal use of tenofovir reduced-glycerin 1% gel at sites with capacity", 
                "measure": "Microflora biomarkers and gene expression from the vaginal and rectal environments", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }, 
            {
                "description": "Determine the timing of vaginal and rectal intercourse around gel insertion among those participants who are heterosexually-active.", 
                "measure": "Timing of intercourse relative to gel insertion", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }, 
            {
                "description": "Determine reports of partner response to vaginal and rectal gel use of the women who disclose product use to their partner", 
                "measure": "Partner response to gel use", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }, 
            {
                "description": "Determine the effect of daily gel use on vaginal and rectal non-sexual practices", 
                "measure": "Effect of gel use on vaginal and rectal non-sexual practices", 
                "safety_issue": "No", 
                "time_frame": "10 weeks"
            }
        ], 
        "overall_contact": {
            "email": "nairg1@ukzn.ac.za", 
            "last_name": "Gonasagrie Nair, MBChB"
        }, 
        "overall_contact_backup": {
            "email": "jj2158@columbia.edu", 
            "last_name": "Jessica Justman, MD", 
            "phone": "212-342-0537"
        }, 
        "overall_official": {
            "affiliation": "Columbia University", 
            "last_name": "Jessica Justman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_outcome": {
            "description": "To compare local and systemic pharmacokinetics of tenofovir reduced-glycerin 1% gel after 2 weeks of daily rectal use and after 2 weeks of daily vaginal use", 
            "measure": "Drug concentrations", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "removed_countries": {
            "country": "South Africa"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768962"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the safety of tenofovir reduced-glycerin 1% gel after 2 weeks of daily rectal use and after 2 weeks of daily vaginal use", 
            "measure": "Number of adverse events Grade 2 or higher", 
            "safety_issue": "Yes", 
            "time_frame": "10 weeks"
        }, 
        "source": "CONRAD", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Division of AIDS", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Institute of Mental Health (NIMH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Institutes of Health (NIH)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "CONRAD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}